AR047958A1 - Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central. - Google Patents
Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central.Info
- Publication number
- AR047958A1 AR047958A1 ARP050100106A ARP050100106A AR047958A1 AR 047958 A1 AR047958 A1 AR 047958A1 AR P050100106 A ARP050100106 A AR P050100106A AR P050100106 A ARP050100106 A AR P050100106A AR 047958 A1 AR047958 A1 AR 047958A1
- Authority
- AR
- Argentina
- Prior art keywords
- dihidro
- ona
- benzo
- derivatives
- alkyl
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004429 atom Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- -1 amidoalkyl Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Métodos de obtencion, composiciones farmacéuticas que los contienen y usos. Reivindicacion 1: Un compuesto de la formula (1), o una sal farmacéuticamente aceptable del mismo, en la que: Y es C o S; m es 1 cuando Y es C y m es 2 cuando Y es S; n es 1 o 2; p es un numero de 0 a 3; q es un numero de 1 a 3; Z es -(CRaRb)r- o -SO2-, en el que r es un numero de 0 a 2 y cada uno de Ra y Rb con independencia entre sí es hidrogeno o alquilo; X es CH o N; cada R1 con independencia de su aparicion es: halogeno; alquilo; haloalquilo; heteroalquilo; alcoxi; ciano; -S(O)s-Rc; -C(=O)-NRcRd; -SO2-NRcRd; -N(Rc)-C(=O)-Rd; o -C(=O)Rc; en el que s es un numero de 0 a 2 y cada uno de Rc y Rd con independencia entre sí es hidrogeno o alquilo; R2 es arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; R2 es con preferencia arilo y con mayor preferencia fenilo opcionalmente sustituido por uno o varios trifluorometilo, halogeno, ciano, alquilo C1-6 o alcoxi C1-6; A es -NR3- U -O- en el que R3 es: hidrogeno; alquilo, acilo, amidoalquilo, hidroxialquilo o alcoxialquilo; R3 es con preferencia hidrogeno, alquilo o amidoalquilo; cada uno de R4 y R5 con independencia entre sí es hidrogeno o alquilo, o uno de R4 y R5 junto con R3 y los átomos situados entre ambos pueden formar un anillo de 3 a 7 eslabones que incluye opcionalmente un heteroátomos de nitrogeno o oxígeno; y cada uno de R6, R7, R8, R9, y R10 con independencia entre sí es hidrogeno o alquilo, o uno de R6 y R7 junto con R10 y los átomos a los que están unidos pueden formar un anillo de 3 a 7 eslabones, o uno de R5 y R7 junto con los átomos a los que están unidos pueden formar un anillo de 3 a 7 eslabones, o uno de R6 y R7 junto con uno de R8 y R9 y los átomos a los que están unidos pueden formar un anillo de 3 a 7 eslabones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53708004P | 2004-01-16 | 2004-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047958A1 true AR047958A1 (es) | 2006-03-15 |
Family
ID=34794441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100106A AR047958A1 (es) | 2004-01-16 | 2005-01-13 | Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7196087B2 (es) |
| EP (1) | EP1708713B1 (es) |
| JP (1) | JP4533391B2 (es) |
| KR (1) | KR100843053B1 (es) |
| CN (1) | CN1909909B (es) |
| AR (1) | AR047958A1 (es) |
| AT (1) | ATE388712T1 (es) |
| AU (1) | AU2005205016B2 (es) |
| BR (1) | BRPI0506909A (es) |
| CA (1) | CA2552681A1 (es) |
| CO (1) | CO5700763A2 (es) |
| DE (1) | DE602005005298T2 (es) |
| ES (1) | ES2302174T3 (es) |
| IL (1) | IL176631A0 (es) |
| NO (1) | NO20062791L (es) |
| RU (1) | RU2006129464A (es) |
| TW (1) | TW200530222A (es) |
| WO (1) | WO2005067933A1 (es) |
| ZA (1) | ZA200605434B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| ES2643615T3 (es) * | 2004-09-30 | 2017-11-23 | F. Hoffmann-La Roche Ag | Composiciones y métodos para el tratamiento de trastornos cognitivos |
| BRPI0519013A2 (pt) * | 2004-12-13 | 2009-11-03 | Lilly Co Eli | composto ou esteroisÈmeros únicos, misturas de esteroisÈmeros, sais, tautÈmeros ou pró-drogas destes farmaceuticamente aceitáveis, composição farmacêutica, e, uso de um composto |
| WO2007006677A1 (en) * | 2005-07-13 | 2007-01-18 | F. Hoffmann-La Roche Ag | Benzimidazole derivatives as 5-ht6,5-ht24 |
| KR100817538B1 (ko) * | 2006-07-05 | 2008-03-27 | 한국화학연구원 | 신규 치환된―１ｈ―퀴나졸린―２,４―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물 |
| WO2008033764A2 (en) * | 2006-09-11 | 2008-03-20 | N.V. Organon | Quinazolinone and isoquinolinone acetamide derivatives |
| US7718652B2 (en) | 2006-12-12 | 2010-05-18 | Wyeth Llc | Substituted benzothiadiazinedioxide derivatives and methods of their use |
| BRPI0822462A2 (pt) * | 2008-06-20 | 2015-10-13 | Rottapharm Spa | derivados de 6-1h-imidazo-quinazolina e de quinolinas, novos inibidores de mao e ligantes a receptor de imidazolina. |
| US8044047B2 (en) | 2008-09-08 | 2011-10-25 | Hoffman-La Roche Inc. | 5-substituted benzoxazines |
| BR112012028964A2 (pt) | 2010-05-21 | 2016-07-26 | Shanghai Inst Pharm Industry | quinazolinas policíclicas, método de preparação das mesmas e seus usos |
| UA125631C2 (uk) | 2016-11-15 | 2022-05-04 | Темпл Юніверсіті-Оф Дзе Коммонвелт Сістем Оф Хайєр Едьюкейшн | Нові модулятори 5-гідрокситриптамінового рецептора 7 і спосіб їх застосування |
| JP7574215B2 (ja) | 2019-04-29 | 2024-10-28 | ソレント セラピューティクス，エルエルシー | ＭＲＧＸ２の阻害薬である３－アミノ－４Ｈ－ベンゾ［ｅ］［１，２，４］チアジアジン１，１－ジオキシド誘導体 |
| CN114929688B (zh) * | 2019-10-21 | 2024-11-01 | 阿莱瑞恩公司 | 作为H1和5-HT2A-受体调节剂、用于治疗睡眠障碍的3-(4-(11H-二苯并[b,e][1,4]吖庚英-6-基)哌嗪-1-基)-和3-(4-(二苯并[b,f][1,4]氧杂吖庚英/硫杂吖庚英/二吖庚英-11-基)哌嗪-1-基)-丙酸衍生物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3642791A (en) * | 1969-08-13 | 1972-02-15 | Sandoz Ag | Morpholino-1-substituted-2(1h)-quinazolinones |
| JPS5271483A (en) * | 1975-12-11 | 1977-06-14 | Sumitomo Chem Co Ltd | Synthesis of 2(1h)-quinazolinone derivatives |
| CN1015459B (zh) * | 1985-06-06 | 1992-02-12 | 田边制药株式会社 | 喹唑啉酮化合物的制备方法 |
| GR1000821B (el) * | 1988-11-22 | 1993-01-25 | Tanabe Seiyaku Co | Μεθοδος παραγωγης παραγωγων κιναζολινονης. |
| AU6908398A (en) | 1996-10-28 | 1998-05-22 | Versicor Inc | Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones |
| AU6423298A (en) | 1997-03-26 | 1998-10-20 | Sumitomo Pharmaceuticals Company, Limited | 4-arylmethylene-1,4-dihydro-2h-azine derivatives |
| SI1028950T1 (en) | 1997-10-28 | 2003-08-31 | Warner-Lambert Company Llc | 7-substituted quinazolin-2,4-diones useful as antibacterial agents |
| AU2074699A (en) * | 1998-01-26 | 1999-08-09 | Yamanouchi Pharmaceutical Co., Ltd. | Novel benzene-fused heterocyclic derivatives or salts thereof |
| EP1228043B1 (en) * | 1999-11-05 | 2005-01-12 | SmithKline Beecham plc | Isoquinoline and quinazoline deivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity |
| EP1248624A4 (en) | 1999-11-23 | 2003-01-22 | Smithkline Beecham Corp | 3,4-DIHYDRO- (1H) -CHIRAZOLINE-2-ONES AND THE USE THEREOF AS CSBP / P38 KINASE INHIBITORS |
| WO2001044228A2 (fr) | 1999-12-14 | 2001-06-21 | Sanofi-Synthelabo | Derives de quinazolinedione et phtalimide, leurs preparations et leurs applications en therapeutique |
| CA2431904A1 (en) * | 2000-12-20 | 2002-08-01 | Merck & Co., Inc. | (halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents |
| US6998408B2 (en) * | 2001-03-23 | 2006-02-14 | Bristol-Myers Squibb Pharma Company | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
| EP1401812B1 (en) * | 2001-06-15 | 2006-06-28 | F. Hoffmann-La Roche Ag | 4-piperazinylindole derivatives with 5-ht6 receptor affinity |
| GB0203804D0 (en) * | 2002-02-18 | 2002-04-03 | Glaxo Group Ltd | Compounds |
| PT1506179E (pt) * | 2002-05-13 | 2006-06-30 | Hoffmann La Roche | Derivados de benzoxazina como moduladores de 5-ht6 e suas utilizacoes |
-
2005
- 2005-01-07 BR BRPI0506909-2A patent/BRPI0506909A/pt not_active IP Right Cessation
- 2005-01-07 CA CA002552681A patent/CA2552681A1/en not_active Abandoned
- 2005-01-07 DE DE602005005298T patent/DE602005005298T2/de not_active Expired - Lifetime
- 2005-01-07 AT AT05700747T patent/ATE388712T1/de active
- 2005-01-07 ES ES05700747T patent/ES2302174T3/es not_active Expired - Lifetime
- 2005-01-07 JP JP2006548231A patent/JP4533391B2/ja not_active Expired - Fee Related
- 2005-01-07 KR KR1020067014320A patent/KR100843053B1/ko not_active Expired - Fee Related
- 2005-01-07 AU AU2005205016A patent/AU2005205016B2/en not_active Ceased
- 2005-01-07 WO PCT/EP2005/000095 patent/WO2005067933A1/en not_active Ceased
- 2005-01-07 CN CN2005800026123A patent/CN1909909B/zh not_active Expired - Fee Related
- 2005-01-07 RU RU2006129464/04A patent/RU2006129464A/ru unknown
- 2005-01-07 EP EP05700747A patent/EP1708713B1/en not_active Expired - Lifetime
- 2005-01-13 TW TW094101029A patent/TW200530222A/zh unknown
- 2005-01-13 AR ARP050100106A patent/AR047958A1/es not_active Application Discontinuation
- 2005-01-14 US US11/035,506 patent/US7196087B2/en not_active Expired - Fee Related
-
2006
- 2006-06-15 NO NO20062791A patent/NO20062791L/no not_active Application Discontinuation
- 2006-06-29 IL IL176631A patent/IL176631A0/en unknown
- 2006-06-30 ZA ZA200605434A patent/ZA200605434B/en unknown
- 2006-07-13 CO CO06068258A patent/CO5700763A2/es not_active Application Discontinuation
-
2007
- 2007-02-07 US US11/703,424 patent/US7365063B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7365063B2 (en) | 2008-04-29 |
| EP1708713A1 (en) | 2006-10-11 |
| ZA200605434B (en) | 2008-02-27 |
| IL176631A0 (en) | 2006-10-31 |
| EP1708713B1 (en) | 2008-03-12 |
| KR100843053B1 (ko) | 2008-07-01 |
| WO2005067933A1 (en) | 2005-07-28 |
| JP2007517826A (ja) | 2007-07-05 |
| ATE388712T1 (de) | 2008-03-15 |
| JP4533391B2 (ja) | 2010-09-01 |
| CA2552681A1 (en) | 2005-07-28 |
| ES2302174T3 (es) | 2008-07-01 |
| BRPI0506909A (pt) | 2007-05-29 |
| NO20062791L (no) | 2006-08-01 |
| US20050165001A1 (en) | 2005-07-28 |
| TW200530222A (en) | 2005-09-16 |
| CN1909909A (zh) | 2007-02-07 |
| RU2006129464A (ru) | 2008-02-27 |
| US7196087B2 (en) | 2007-03-27 |
| CO5700763A2 (es) | 2006-11-30 |
| DE602005005298T2 (de) | 2009-03-12 |
| AU2005205016A1 (en) | 2005-07-28 |
| AU2005205016B2 (en) | 2010-07-15 |
| CN1909909B (zh) | 2010-12-15 |
| KR20060126720A (ko) | 2006-12-08 |
| US20070149510A1 (en) | 2007-06-28 |
| DE602005005298D1 (de) | 2008-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061372A1 (es) | Amino-imidazoles y sus usos como medicamentos para el tratamiento de mal de alzheimer, demencia y neurodegeneracion | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| AR076170A1 (es) | Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. | |
| AR047958A1 (es) | Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central. | |
| AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
| AR044037A1 (es) | Compuestos de pirazol e imidazol biciclicos como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos | |
| ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| AR058010A1 (es) | Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto | |
| AR050281A1 (es) | Derivados de indol, indazol e indazolina. procesos de obtencion y composiciones farmaceuticas | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR076754A1 (es) | Dihidropirimidinas y proceso de obtencion de las mismas | |
| UY31014A1 (es) | Derivados de ftalazinona | |
| AR062965A1 (es) | Compuestos moduladores de receptores de glutamatometabotropicos mglur5, composiciones farmaceuticas que los contienen y usos terapeuticos en trastornos gastrointestinales, neurologicos y psiquiatricos agudos y cronicos | |
| AR061603A1 (es) | Derivados de etenilcarboxamidas microbicidas | |
| AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
| CO6160307A2 (es) | Compuestos de pirazolina y su uso y composiciones farmaceuticas | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| AR073565A1 (es) | Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen | |
| AR060813A1 (es) | Moduladores de mglur5 iii | |
| AR039988A1 (es) | Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos | |
| AR042002A1 (es) | Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |